BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37225761)

  • 1. Ambra1 modulates the sensitivity of mantle cell lymphoma to palbociclib by regulating cyclin D1.
    Jiang Z; Zhang A; Wei W; Li S
    Sci Rep; 2023 May; 13(1):8389. PubMed ID: 37225761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.
    Heine S; Kleih M; Giménez N; Böpple K; Ott G; Colomer D; Aulitzky WE; van der Kuip H; Silkenstedt E
    J Hematol Oncol; 2018 Sep; 11(1):112. PubMed ID: 30180865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.
    Marzec M; Kasprzycka M; Lai R; Gladden AB; Wlodarski P; Tomczak E; Nowell P; Deprimo SE; Sadis S; Eck S; Schuster SJ; Diehl JA; Wasik MA
    Blood; 2006 Sep; 108(5):1744-50. PubMed ID: 16690963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.
    Wang K; Huang X; Di Liberto M; Chen-Kiang S
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):809-823. PubMed ID: 32861279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib.
    Chaturvedi NK; Hatch ND; Sutton GL; Kling M; Vose JM; Joshi SS
    Leuk Lymphoma; 2019 May; 60(5):1214-1223. PubMed ID: 30424705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
    Shirsath NP; Manohar SM; Joshi KS
    Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.
    Beltran E; Fresquet V; Martinez-Useros J; Richter-Larrea JA; Sagardoy A; Sesma I; Almada LL; Montes-Moreno S; Siebert R; Gesk S; Calasanz MJ; Malumbres R; Rieger M; Prosper F; Lossos IS; Piris MA; Fernandez-Zapico ME; Martinez-Climent JA
    Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12461-6. PubMed ID: 21746927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.
    Moros A; Bustany S; Cahu J; Saborit-Villarroya I; Martínez A; Colomer D; Sola B; Roué G
    Clin Cancer Res; 2014 Jan; 20(2):393-403. PubMed ID: 24178620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.
    Martin P; Ruan J; Furman R; Rutherford S; Allan J; Chen Z; Huang X; DiLiberto M; Chen-Kiang S; Leonard JP
    Leuk Lymphoma; 2019 Dec; 60(12):2917-2921. PubMed ID: 31120355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma.
    Guidoboni M; Zancai P; Cariati R; Rizzo S; Dal Col J; Pavan A; Gloghini A; Spina M; Cuneo A; Pomponi F; Bononi A; Doglioni C; Maestro R; Carbone A; Boiocchi M; Dolcetti R
    Cancer Res; 2005 Jan; 65(2):587-95. PubMed ID: 15695403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D.
    Chaikovsky AC; Li C; Jeng EE; Loebell S; Lee MC; Murray CW; Cheng R; Demeter J; Swaney DL; Chen SH; Newton BW; Johnson JR; Drainas AP; Shue YT; Seoane JA; Srinivasan P; He A; Yoshida A; Hipkins SQ; McCrea E; Poltorack CD; Krogan NJ; Diehl JA; Kong C; Jackson PK; Curtis C; Petrov DA; Bassik MC; Winslow MM; Sage J
    Nature; 2021 Apr; 592(7856):794-798. PubMed ID: 33854239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
    Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
    Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV.
    de Vos S; Krug U; Hofmann WK; Pinkus GS; Swerdlow SH; Wachsman W; Grogan TM; Said JW; Koeffler HP
    Diagn Mol Pathol; 2003 Mar; 12(1):35-43. PubMed ID: 12605034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma.
    Yatabe Y; Suzuki R; Tobinai K; Matsuno Y; Ichinohasama R; Okamoto M; Yamaguchi M; Tamaru J; Uike N; Hashimoto Y; Morishima Y; Suchi T; Seto M; Nakamura S
    Blood; 2000 Apr; 95(7):2253-61. PubMed ID: 10733493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.
    Prasad A; Park IW; Allen H; Zhang X; Reddy MV; Boominathan R; Reddy EP; Groopman JE
    Oncogene; 2009 Mar; 28(12):1518-28. PubMed ID: 19198627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.
    Chiron D; Martin P; Di Liberto M; Huang X; Ely S; Lannutti BJ; Leonard JP; Mason CE; Chen-Kiang S
    Cell Cycle; 2013 Jun; 12(12):1892-900. PubMed ID: 23676220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma.
    Izban KF; Alkan S; Singleton TP; Hsi ED
    Arch Pathol Lab Med; 2000 Oct; 124(10):1457-62. PubMed ID: 11035575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
    Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
    Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No evidence of cell cycle dysregulation in mantle cell lymphoma in vivo.
    Vogt N; Abramov D; Koch K; Masqué-Soler N; Szczepanowski M; Klapper W
    Leuk Lymphoma; 2015 Jul; 56(7):2134-40. PubMed ID: 25315075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice.
    Vincent-Fabert C; Fiancette R; Rouaud P; Baudet C; Truffinet V; Magnone V; Guillaudeau A; Cogné M; Dubus P; Denizot Y
    Am J Pathol; 2012 Apr; 180(4):1688-701. PubMed ID: 22326754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.